iZafe Group ABFRA:M02 -5.06%48 Days Payable is 312.10 as of Mar. 2026, which is 9% below its 10-year median of 341.80. GuruFocus rates FRA:M02 with a GF Score™ of 48/100 and a GF Value™ of €0.04 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, iZafe Group AB ranks better than 82.77% on this metric.
The historical rank and industry rank for iZafe Group AB's Days Payable or its related term are showing as below:
FRA:M02'
s Days Payable Range Over the Past 10 Years
Min: 90.11 Med: 341.8 Max: 1321.13
Current: 178.34
During the past 13 years, iZafe Group AB's highest Days Payable was 1321.13. The lowest was 90.11. And the median was 341.80.
FRA:M02's Days Payable is ranked better than 82.77% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs FRA:M02: 178.34
iZafe Group AB's Days Payable
increased
from Mar. 2025 (215.23) to Mar. 2026 (312.10).
It may suggest that iZafe Group ABdelayed paying its suppliers.
iZafe Group AB Days Payable Related Terms
iZafe Group AB Days Payable Historical Data
* Premium members only.
The historical data trend for iZafe Group AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M02 vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, iZafe Group AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iZafe Group AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iZafe Group AB's Days Payable distribution charts can be found below:
* The bar in red indicates where iZafe Group AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
iZafe Group AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iZafe Group AB (FRA:M02) has a Days Payable of 312.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on iZafe Group AB and its competitors. This is near median its historical median of 341.80. Over the past decade, iZafe Group AB's Days Payable has ranged from 90.11 to 1,321.13. According to the industry distribution chart, iZafe Group AB ranks #137 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 17.2%.
Is iZafe Group AB's Days Payable too high?
iZafe Group AB's current Days Payable of 312.10 is near median its 10-year median of 341.80. Over the past 10 years, this metric has ranged from a low of 90.11 to a high of 1,321.13. The Medical Devices & Instruments industry median Days Payable is 67.87. iZafe Group AB's value of 312.10 is 359.8% above this industry median. Based on the distribution chart, iZafe Group AB ranks #137 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iZafe Group AB has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iZafe Group AB's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, iZafe Group AB ranks #137 out of 795 companies for Days Payable. This places iZafe Group AB in the top 17% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.87. iZafe Group AB's value of 312.10 is 359.8% above this benchmark. Historically, iZafe Group AB's own Days Payable has ranged from 90.11 to 1,321.13 over the past decade. While the company's 10-year median is 341.80 vs. the industry median of 67.87, iZafe Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iZafe Group AB's current Days Payable of 312.10 is 359.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on iZafe Group AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iZafe Group AB's current Days Payable is 312.10, which is near median its own 10-year median of 341.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iZafe Group AB stock overvalued right now?
Based on GuruFocus' analysis, iZafe Group AB (FRA:M02) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.04, compared to a current price of €0.03 — trading 15.5% below its estimated fair value. The current Days Payable is 312.10, which is near median its 10-year median of 341.80 and 359.8% above the Medical Devices & Instruments industry median of 67.87. iZafe Group AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For iZafe Group AB (FRA:M02), the current Days Payable is 312.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iZafe Group AB (FRA:M02) Overvalued in 2026?
Based on GuruFocus' analysis, iZafe Group AB stock appears to be undervalued.
The current stock price of €0.03 is trading 15.5% below its estimated GF Value™ of €0.04.
GuruFocus considers iZafe Group AB to be Modestly Undervalued.
Key valuation signals for FRA:M02:
Days Payable: 312.10 (near median its 10-year median of 341.80)
GF Value™: €0.04 vs. price of €0.03 (15.5% below fair value)
Industry Position: 359.8% above the Medical Devices & Instruments median (#137 of 795)
No single metric tells the full story. See the FRA:M02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iZafe Group AB is a Developer of a digital medication dispensing system designed to enhance patient safety and reduce medication errors in home healthcare. The company offers a smart medication robot with automated dispensing and remote monitoring, enabling public and private healthcare providers in Sweden, the Nordics, and international markets, improved treatment adherence and reduced caregiver workload.
48GF Score
Get the complete analysis for FRA:M02
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M02 has been successfully added to your 
